Streetbeat News

Products Services

NVDA

Nvidia Corp. (NASDAQ:NVDA) has seen a nearly 50% increase in stock price in the first six weeks of 2024, driven by the AI buzz. The company, known for its GPUs, is now competing closely with Amazon and Google in market cap. Nvidia's GPUs, crucial in gaming, cryptocurrency mining, and now AI, have been instrumental in the company's growth. The GeForce 256, launched in 1999, was Nvidia's significant contribution, marking the introduction of the world's first GPU. Nvidia's stock has surged 151,261% since its first GPU launch, significantly outperforming the Nasdaq and S&P 500 indices. CEO Jensen Huang's wealth has also increased by nearly 50% in 2024, reaching $63.8 billion.

Portfolio Pulse from Rounak Jain

February 14, 2024 | 12:17 pm

DTIL

Precision BioSciences has received positive pre-IND feedback from the FDA for its PBGENE-HBV program, supporting its clinical development path. The company is conducting IND/CTA enabling studies and plans to file for IND and/or CTA in 2024. PBGENE-HBV aims to be the first potentially curative gene editing program for eliminating cccDNA and inactivating integrated HBV DNA.

Portfolio Pulse from Benzinga Newsdesk

February 14, 2024 | 12:15 pm

VEEV

Veeva Systems Inc. has announced a partnership with Boehringer Ingelheim to enhance clinical and regulatory operations in the animal health sector. This collaboration aims to streamline processes and improve efficiencies in bringing new animal health solutions to market.

Portfolio Pulse from Benzinga Newsdesk

February 14, 2024 | 12:12 pm

BMY

The FDA has accepted Bristol Myers Squibb's application for priority review of Augtyro (repotrectinib) for NTRK-Positive locally advanced or metastatic solid tumors, with a target action date of June 15.

Portfolio Pulse from Benzinga Newsdesk

February 14, 2024 | 12:00 pm

BMY

GILD

PFE

Wall Street's most accurate analysts have provided updates on three high-yield dividend health care stocks: Pfizer Inc. (PFE), Bristol-Myers Squibb Company (BMY), and Gilead Sciences, Inc. (GILD). Pfizer's dividend yield is 6.23%, with mixed analyst ratings and a recent expansion of its agreement with Saama for AI-driven data solutions. Bristol-Myers Squibb, with a 4.93% dividend yield, received a downgrade and a price target cut but reported a revenue increase in Q4. Gilead Sciences, offering a 4.19% dividend yield, also saw price target adjustments and recently announced the acquisition of CymaBay Therapeutics.

Portfolio Pulse from Avi Kapoor

February 14, 2024 | 11:54 am

CLNE

Clean Energy has announced the commencement of production at its renewable natural gas facility located at Marshall Ridge Dairy in Iowa. This marks a significant step for the company in expanding its renewable energy portfolio and contributing to environmental sustainability.

Portfolio Pulse from Benzinga Newsdesk

February 14, 2024 | 11:37 am

GRVY

Gravity Co., Ltd. (GRVY) announced preliminary unaudited results for the fourth quarter, expecting a 17.1% decrease in revenue year-over-year. The company also revealed plans to launch Ragnarok Origin in China during the first half of 2024.

Portfolio Pulse from Benzinga Newsdesk

February 14, 2024 | 11:31 am

IREN

NVDA

Iris Energy announced a significant expansion of its AI cloud services business, tripling its capacity to 816 NVIDIA H100 GPUs. This move indicates Iris Energy's aggressive push into the AI and cloud computing markets, leveraging NVIDIA's advanced GPU technology.

Portfolio Pulse from Benzinga Newsdesk

February 14, 2024 | 11:26 am

MAXN

Maxeon Solar Technologies announced the completion of its first customer installation using the next generation Maxeon Interdigitated Back Contact (IBC) solar panels. This marks a significant milestone for the company in the deployment of its advanced solar technology.

Portfolio Pulse from Benzinga Newsdesk

February 14, 2024 | 11:11 am

GBTC

HOOD

Bitcoin traders are targeting a $64,000 price point as BlackRock's iShares Bitcoin ETF (IBIT) sees a $500 million inflow in one day. The overall inflow into Bitcoin ETFs reached nearly $630 million, with IBIT leading among 11 providers. This surge in ETF interest and a decrease in outflows from Grayscale's Bitcoin Trust (GBTC) have contributed to a bullish sentiment in the market. Bitcoin's price rose over $51,000, and options traders are betting on it surpassing its all-time high of $69,000. Robinhood noted Bitcoin ETFs make up about 5% of its crypto trading volume.

Portfolio Pulse from Benzinga Neuro

February 14, 2024 | 11:09 am